• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

    5/13/24 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HROW alert in real time by email

    Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division.

    DiPasquale joins Harrow from Regeneron Pharmaceuticals, Inc., where he served as National Business Director and was responsible for key account management and national sales of the anti-VEGF products EYLEA® and EYLEA® HD for its two highest volume indications. Under his leadership, sales of products under Greg's portfolio grew from $4.5 billion to over $6 billion during a four-year period. Prior to this role, DiPasquale was Vice President and Head of Sales for the newly formed Retina Division of Novartis Ophthalmology, where he oversaw the development of the division's sales infrastructure, spearheaded the launch of BEOVU®, and expanded the entire retina and ophthalmology product pipeline, generating over $1 billion in revenues in 2020. DiPasquale's extensive experience also includes executive leadership positions at Bausch + Lomb as Vice President of Sales for the U.S. Vision Care business, at Zeiss Vision Care as Senior Vice President, with responsibility for profit and loss for its eyecare professional practice and the management of multiple lab operations and sales personnel throughout the U.S., and at Essilor USA. DiPasquale holds a Bachelor's in Business Administration (BBA) from Ohio University and an Executive MBA from Kent State University. DiPasquale will be based in Harrow's Nashville, Tennessee, corporate headquarters.

    Commenting on DiPasquale's addition to the Harrow team, Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said, "Over the last 16 years of Greg's remarkable career, he has delivered outstanding economic and commercial results, playing a pivotal role in commercializing several highly successful ophthalmic pharmaceutical products. We are particularly excited about Greg's experience and proven success serving the buy-and-bill, retina, and optometric markets given our recent launches of IHEEZO® and our plans to re-launch TRIESENCE® – products with large retina market opportunities – and our strong launch of VEVYE®, which has been so positively embraced by the medical optometric market as well as by ophthalmologists across the country. We are confident that Greg's strategic acumen and track record of expanding major ophthalmic pharmaceutical franchises will prove invaluable to our success as we continue to leverage our branded product portfolio and execute our strategic plan to position Harrow as a leader in the North American ophthalmic pharmaceutical market."

    DiPasquale added, "I am exceedingly enthusiastic about joining Harrow, a dynamic, visionary, and service‑oriented company committed to enhancing patient access to critical eyecare medications. Leaders in eyecare have watched with admiration as Harrow has evolved into a significant strategic player in the ophthalmic pharmaceutical industry, starting from scratch with its ImprimisRx franchise and subsequently acquiring 18 branded products over the past two years. I look forward to utilizing the knowledge and experience gained throughout my 30+ year career to advance Harrow's broad array of branded products, including, among others, IHEEZO, VEVYE, and soon TRIESENCE, and to working with the talented and dedicated Harrow team to take our company to the next level."

    About Harrow

    Harrow, Inc. (NASDAQ:HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240513390675/en/

    Get the next $HROW alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HROW

    DatePrice TargetRatingAnalyst
    7/11/2025$76.00Overweight
    Cantor Fitzgerald
    6/12/2025$62.00Buy
    BTIG Research
    6/10/2025Outperform
    William Blair
    2/6/2025$57.00Buy
    H.C. Wainwright
    12/4/2024$73.00 → $69.00Buy
    B. Riley Securities
    4/11/2024$24.00Buy
    Craig Hallum
    9/8/2022$17.00Buy
    B. Riley Securities
    10/14/2021$16.00Buy
    B. Riley Securities
    More analyst ratings

    $HROW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Opaleye Management Inc. bought $199,400 worth of shares (20,000 units at $9.97) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/25/24 5:19:24 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opaleye Management Inc. bought $204,640 worth of shares (20,000 units at $10.23) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/24/24 4:40:20 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opaleye Management Inc. bought $310,390 worth of shares (29,400 units at $10.56) (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    4/19/24 6:24:32 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Harrow with a new price target

    Cantor Fitzgerald initiated coverage of Harrow with a rating of Overweight and set a new price target of $76.00

    7/11/25 8:12:59 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Harrow with a new price target

    BTIG Research initiated coverage of Harrow with a rating of Buy and set a new price target of $62.00

    6/12/25 7:54:43 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Harrow

    William Blair initiated coverage of Harrow with a rating of Outperform

    6/10/25 8:09:06 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF ACCOUNTING OFFICER Pollard Randall E.

    4 - HARROW, INC. (0001360214) (Issuer)

    9/9/25 9:07:57 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Pollard Randall E.

    3 - HARROW, INC. (0001360214) (Issuer)

    9/9/25 9:04:56 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Baum Mark L covered exercise/tax liability with 313,338 shares and exercised 600,000 shares at a strike of $7.87, increasing direct ownership by 11% to 2,886,124 units (SEC Form 4)

    4 - HARROW, INC. (0001360214) (Issuer)

    7/23/25 9:10:48 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    SEC Filings

    View All

    $HROW
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amendment: Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K/A - HARROW, INC. (0001360214) (Filer)

    10/1/25 7:39:13 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    9/29/25 7:00:47 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HARROW, INC. (0001360214) (Filer)

    9/26/25 4:05:58 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow to Acquire Melt Pharmaceuticals

    NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. The closing of this acquisition is subject to customary closing conditions, including approval by Melt stockholders, excluding Harrow and Harrow-affiliated parties. Melt's lead investigational therapy, MELT-300, is a patented, sublingually delivered formulation of a fixed dose o

    9/26/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Launches Harrow Access for All (HAFA)

    HAFA to Expand Harrow's Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of Harrow Access for All ("HAFA"), expanding Harrow's commitment to make it easier and more affordable for patients to access Harrow's full range of branded, generic, and compounded ophthalmic medications. HAFA builds on the success of the VEVYE® Access for All ("VAFA") initiative, which launched in March 2025 with a strong reception from both physician

    9/25/25 4:05:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Announces Agenda and Speakers for Investor & Analyst Day

    NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the agenda for its upcoming Investor & Analyst Day on Friday, September 26, from 11:30 a.m. ET to 3 p.m. ET in New York. The event will also be webcast live and instructions for accessing the webcast are below. Harrow's Investor & Analyst Day will include a comprehensive overview of Harrow's business, featuring presentations from the Company's leadership team covering the full scope of Harrow's commercial portfolio, pipeline, and long-term vision. In addition, the program will include presentations from renowned physici

    9/15/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Leadership Updates

    Live Leadership Updates

    View All

    Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. "We are excited to welcome Mike to the Harrow Family. His wealth of experience in investor relations and strategic communications will be a tremendous asset as we pursue our objective of becoming the leading U.S. ophthalmic pharmaceutical company," said Mark L. Baum, Chief Executive Officer of Harrow. "I a

    6/18/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P

    1/7/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

    Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale

    5/13/24 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Financials

    Live finance-specific insights

    View All

    Harrow Announces Second-Quarter 2025 Financial Results

    Second-Quarter 2025 and Recent Selected Highlights: Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year periodGAAP net income of $5.0 millionAdjusted EBITDA of $17.0 millionCash and cash equivalents of $53.0 million as of June 30, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the second quarter ended June 30, 2025. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the "Investors" s

    8/11/25 4:01:00 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

    NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, August 12, 2025, to discuss the results and provide a business update. Conference Call InformationParticipants can access the live webcast of Harrow's presentation on the "Investors" page of Harrow'

    7/29/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

    Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15 years. Harrow expects BYQLOVI to be available in the fourth quarter of 2025. This press release features multimedia. View the full release here: https://www.busin

    6/9/25 7:00:00 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HROW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    12/5/24 7:08:52 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Harrow Inc.

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    10/8/24 6:41:41 AM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harrow Inc. (Amendment)

    SC 13G/A - HARROW, INC. (0001360214) (Subject)

    2/13/24 5:25:53 PM ET
    $HROW
    Biotechnology: Pharmaceutical Preparations
    Health Care